Market and company headlines
Amphastar Pharmaceuticals has seen its share price move around in recent years, which puts a spotlight on whether the current US$25.87 level lines up with what its earnings really support. For anyone tracking the drug maker today, the key issue is how that recent price path squares with the profits the business is generating. The stock has declined 41.9% over the past 3 years, which raises the question of whether earnings now fully explain that reset in market expectations. The business...
Yahoo·21:11·11 Days AgoAMPH▲+0.4%
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Yahoo·08:40AMPH▲+0.4%
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.
Yahoo·07:57
Amphastar is rated a Hold, and shares have dropped over 40%, now trading at ~$26.5 with a $1.1bn market cap. Read more on AMPH stock here.
SeekingAlpha·11:41AMPH▲+0.4%
Over the past six months, Amphastar Pharmaceuticals has been a great trade, beating the S&P 500 by 11.4%. Its stock price has climbed to $24.97, representing a healthy 29.8% increase. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Yahoo·11:44AMPH▲+0.4%
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.
Yahoo·06:06
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
Yahoo·17:04
Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the now-completed Q2 generic pharmaceuticals earnings season.
Yahoo·09:06AMPH▲+0.4%
Amphastar (AMPH) passes quality screen with 17.2% ROIC, 104% profit quality, and cheap valuation, but revenue growth lags.
ChartMill·06:31AMPH▲+0.4%
